Indeed, it was previously reported that although the use of PI3K-AKT-mTOR pathway inhibitors and inhibitors of other molecular pathways implicated in breast cancer (such as cyclin-dependent kinase 4/6 signaling pathway) had demonstrated being effective in prolonging progression-free survival of breast cancer patients, an increase in overall survival was generally not observed [48]. This evidence concerns the gene CDK4 and breast carcinoma.